NTLA news

Intellia has completed its field organization deployment and strengthened engagement with payers for its HAE treatment lonvo-z. The stock is reacting positively to the data ahead of a March 10, 2027 PDUFA date.

The company secured a $400 million facility for HAE drug lonvo-z and pipeline programs, enhancing financial flexibility without shareholder dilution.

Intellia released positive Phase 3 data for its HAE treatment lonvo-z, received FDA guidance, and ended the quarter with strong liquidity.

Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, achieving 87% reduction in attacks versus placebo with 62% of patients attack-free. The in vivo CRISPR gene editing therapy results were published in NEJM and could support a potential regulatory submission.